BioPharmSignal logoBioPharmSignal

Biotech News

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Regeneron Pharmaceuticals (REGN)Regeneron PharmaceuticalsCompany update

Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and

Open original release

Related news

REGNRegeneron Pharmaceuticals2026-05-15 18:09 EST

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

REGNRegeneron Pharmaceuticals2026-05-18 11:00 EST

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

BNTXBioNTech2026-05-22 09:00 EST

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

BMYBMYBristol-Myers Squibb Company2026-06-08 10:59 EST

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

SNDXSyndax Pharmaceuticals2026-06-01 11:00 EST

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

TEVATeva Pharmaceutical Industries2026-06-08 12:00 EST

Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care

TEVATeva Pharmaceutical Industries2026-06-05 15:30 EST

Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea

ZNTLZentalis2026-05-21 21:39 EST

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

View all latest news

Regeneron Pharmaceuticals

Regeneron is a biotechnology company built around antibody discovery, biologics development, and marketed therapies across eye disease, immunology, and oncology. The company’s platform and R&D engine make it one of the most scientifically respected names in public biotech.

Recent company news

REGNRegeneron Pharmaceuticals2026-06-04 11:00 EST

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

REGNRegeneron Pharmaceuticals2026-05-28 20:00 EST

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

REGNRegeneron Pharmaceuticals2026-05-22 11:00 EST

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

REGNRegeneron Pharmaceuticals2026-05-21 21:01 EST

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

REGNRegeneron Pharmaceuticals2026-05-18 11:00 EST

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Stock data

Close
667.17 USD
Market cap
63.21B USD
Exchange
NASDAQ
Sector
Antibody Drugs, Biopharma
Location
United States